A61K 2039/86
Lung
Official title: {Lung}
A61K2039/86 (Lung) appears on 75 US grants and 213 published applications in this corpus.
Search patents in A61K- Granted patents
- 75
- Published applications
- 213
- Assignees
- 112
- Inventors
- 448
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 3 |
| 2003 | 0 | 0 |
| 2004 | 0 | 3 |
| 2005 | 0 | 0 |
| 2006 | 0 | 2 |
| 2007 | 0 | 0 |
| 2008 | 1 | 1 |
| 2009 | 0 | 1 |
| 2010 | 0 | 2 |
| 2011 | 1 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 2 |
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 1 | 5 |
| 2017 | 0 | 3 |
| 2018 | 1 | 4 |
| 2019 | 4 | 16 |
| 2020 | 2 | 29 |
| 2021 | 10 | 26 |
| 2022 | 6 | 28 |
| 2023 | 15 | 19 |
| 2024 | 14 | 36 |
| 2025 | 14 | 22 |
| 2026 | 6 | 10 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Oncolytic virus in combination with immune checkpoint inhibitor for treating tumors15 Sep 2026US 12,734,202 B2Joint Biosciences (Sh) Ltd.
- Intracellular delivery of biomolecules to modify immune response8 Sep 2026US 12,728,163 B2Stemcell Technologies Canada Inc.
- Immunotherapy targeting tumor neoantigenic peptides12 May 2026US 12,622,926 B2Institut Curie
- Neoantigen immunotherapies10 Mar 2026US 12,569,546 B2Iogenetics, LLC
- Treatment of NSCLC patients with tumor infiltrating lymphocyte therapies17 Feb 2026US 12,553,029 B2Iovance Biotherapeutics, Inc.
- Compositions and methods for treatment or prventative treatment of cancer including triple negative breast cancer and/or lung cancer24 Sep 2026US 2026/0284165 A1The Medical College of Wisconsin, Inc.
- Administration of bacterial composition for use in treatment of lung metastases3 Sep 2026US 2026/0256901 A1Immuvera Therapeutics AS
- Tumor cell vaccines20 Aug 2026US 2026/0240969 A1Neuvogen, Inc.
- Neoantigen immunotherapies20 Aug 2026US 2026/0240970 A1Iogenetics, LLC
- Interleukin-15, PD-1 Antibodies, and Taxanes in Non-Small Cell Lung Cancer11 Jun 2026US 2026/0159571 A1ImmunityBio, Inc.
Most cited
By later US patents
- Composition for treating lung cancer, particularly of non-small lung cancers (NSCLC)32US 9,352,028 B2CureVac AG · 2016
- Tissue targeted antigenic activation of the immune response to cancers14US 8,034,359 B2Qu Biologics Inc. · 2011
- Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers7US 10,400,011 B2Immatics Biotechnologies GmbH · 2019
- Chimeric antigen receptor containing a toll-like receptor intracellular domain6US 10,093,717 B2Shenzhen In Vivo Biomedicine Technology Limited Company · 2018
- Compositions and method for optimized peptide vaccines using residue optimization6US 11,464,842 B1Think Therapeutics, Inc. · 2022